{
    "clinical_study": {
        "@rank": "65437", 
        "arm_group": {
            "arm_group_label": "Enzalutamide", 
            "arm_group_type": "Experimental", 
            "description": "160 mg administered as four 40 mg soft gelatin capsules orally once daily"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if enzalutamide is safe and effective in the\n      treatment of patients with advanced breast cancer that express the androgen receptor but do\n      not express the estrogen or progesterone receptor and are not Her2 amplified."
        }, 
        "brief_title": "Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced, Androgen Receptor Positive Triple Negative Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women at least 18 years of age;\n\n          -  Advanced AR+ TNBC;\n\n          -  Availability of a representative tumor specimen:\n\n          -  Either measurable disease or bone only nonmeasurable disease;\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n        Exclusion Criteria:\n\n          -  Any severe concurrent disease, infection, or comorbid condition;\n\n          -  Any condition or reason that interferes with the patient's ability to participate in\n             the trial, that may cause undue risk, or complicates the interpretation of safety\n             data;\n\n          -  Current or previously treated brain metastasis or active leptomeningeal disease;\n\n          -  Current hormone replacement therapy;\n\n          -  Local palliative radiation therapy within 7 days before day 1;\n\n          -  History of another invasive cancer within 5 years of day 1;\n\n          -  Absolute neutrophil count < 1500/\u00b5L, platelet count < 75,000/\u00b5L, or hemoglobin < 9\n             g/dL (5.6 mmol/L) at the screening visit;\n\n          -  Creatinine > 1.5 times ULN at the screening visit;\n\n          -  History of seizure or any condition that may predispose to seizure;\n\n          -  Clinically significant cardiovascular disease;\n\n          -  Active gastrointestinal disorder affecting absorption;\n\n          -  Major surgery within 4 weeks before day 1;\n\n          -  Treatment with any commercially available anticancer agent within 14 days before day\n             1;\n\n          -  Treatment with any investigational agent within 2 weeks before day 1;\n\n          -  Treatment with any of the following medications within 2 weeks before day 1:\n             Estrogens, including hormone replacement therapy; Androgens (testosterone,\n             dihydroepiandrosterone, etc);Systemic radionuclides (eg, samarium or\n             strontium);Vaccine therapy;\n\n          -  Hypoglycemic episode requiring medical intervention while on insulin treatment within\n             12 months before day 1;\n\n          -  Hypersensitivity reaction to the active pharmaceutical ingredient or any of the\n             capsule components, including Labrasol, butylated hydroxyanisole, and butylated\n             hydroxytoluene."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "95", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01889238", 
            "org_study_id": "MDV3100-11", 
            "secondary_id": "2013 000698 57"
        }, 
        "intervention": {
            "arm_group_label": "Enzalutamide", 
            "description": "160 mg administered as four soft gelatin capsules orally once daily", 
            "intervention_name": "Enzalutamide", 
            "intervention_type": "Drug", 
            "other_name": [
                "Xtandi\u00ae", 
                "MDV3100"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Androgens"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "breast cancer", 
            "triple negative", 
            "androgen receptor positive"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80228"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33916"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60675"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55407"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greensboro", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27403"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37204"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77024"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75702"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23230"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilrijk", 
                        "country": "Belgium", 
                        "state": "Antwerpen", 
                        "zip": "2610"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galway", 
                        "country": "Ireland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limerick", 
                        "country": "Ireland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada", 
                "Ireland", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Single Arm, Open Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor Positive, Triple Negative Breast Cancer", 
        "other_outcome": [
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "\u2265 16 weeks"
            }, 
            {
                "description": "To determine the extent of androgen receptor (AR) expression and signaling in breast tissue and to evaluate the relationship of this expression with enzalutamide effects on circulating tumor biomarkers, circulating hormones, and clinical outcomes.", 
                "measure": "Androgen Receptor Expression", 
                "safety_issue": "No", 
                "time_frame": "\u2265 16 weeks"
            }
        ], 
        "overall_contact": {
            "email": "breastcancertrials@medivation.com", 
            "last_name": "Jane Dennison", 
            "phone": "855-349-1891"
        }, 
        "overall_official": {
            "affiliation": "Medivation, Inc.", 
            "last_name": "Amy Peterson, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine clinical benefit rate, defined as the proportion of evaluable patients with androgen receptor positive (AR+), triple negative breast cancer (TNBC) with a best response of complete response (CR), partial response (PR), or stable disease (SD) \u2265 16 weeks.", 
            "measure": "Clinical Benefit Rate", 
            "safety_issue": "No", 
            "time_frame": "\u2265 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01889238"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine clinical benefit rate, defined as the proportion of evaluable patients with a best response of Complete Response, Partial Response, or Stable Disease \u2265 24 weeks;", 
                "measure": "Clinical Benefit Rate", 
                "safety_issue": "No", 
                "time_frame": "\u2265 24 weeks"
            }, 
            {
                "measure": "Best Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "\u2265 16 weeks"
            }, 
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "\u2265 16 weeks"
            }, 
            {
                "measure": "Time to Response", 
                "safety_issue": "No", 
                "time_frame": "\u2265 16 weeks"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "\u2265 16 weeks"
            }, 
            {
                "description": "To assess the pharmacokinetics (PK) of enzalutamide and its active metabolite N desmethyl enzalutamide", 
                "measure": "Pharmacokinetics - Ctrough", 
                "safety_issue": "No", 
                "time_frame": "\u2265 16 weeks"
            }
        ], 
        "source": "Medivation, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medivation, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}